Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia

• Published in: Vaccines (Basel) Vol. 11; no. 2; p. 423
• Main Authors: Mlakar, Jana, Oštrbenk Valenčak, Anja, Kežar, Jožefa, Beseničar-Pregelj, Lara, Poljak, Mario
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12.02.2023; MDPI
• Subjects: Acceptability; adult women; Analysis; Cervical cancer; Children & youth; Consent; Data collection; Disease prevention; Education; Gynecology; Health aspects; Health attitudes; HPV vaccination; Human papillomavirus; Immunization; Infections; Medical personnel; Medical screening; Prevention; Questionnaires; Safety; Slovenia; Vaccines; Women; Womens health; Slovenia; Belgium; France; Europe; Slovenia; HPV vaccination; adult women; acceptability
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11020423

HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25-45 years old women. A total of 607 women from Slovenia participated in the study, and 49.6% (301/607) agreed with HPV vaccination, with a significant difference ( < 0.0001) between the two centers. Non-vaccinated women had a higher education ( = 0.0068) and were more frequently in a committed relationship or married ( = 0.01). The most trusted source of medical and vaccination information was healthcare providers (55.2%). The main reasons for vaccine acceptance were protection against HPV-related disease (93.4%), severity of preventable diseases (82.7%), HPV vaccine safety (66.8%), free HPV vaccine availability (62.8%), and the existence of vaccination recommendations (55.5%). The main reasons for refusing vaccination were the need for additional vaccine-related information (31.4%) and vaccine safety concerns (29.4%). To increase vaccine coverage, information about the benefits and safety of HPV vaccination must be widely disseminated to all health professionals and the general public. We are convinced that the knowledge obtained in this study can be reliably applied to other countries in the region that lack such information and have a very high cervical cancer burden.